Literature DB >> 2803239

The low C5 convertase activity of the C4A6 allotype of human complement component C4.

T Kinoshita1, A W Dodds, S K Law, K Inoue.   

Abstract

We have compared the C5-convertase-forming ability of different C4 allotypes, including the C4A6 allotype, which has low haemolytic activity and which has previously been shown to be defective in C5-convertase formation. Recent studies suggest that C4 plays two roles in the formation of the C5 convertase from the C3 convertase. Firstly, C4b acts as the binding site for C3 which, upon cleavage by C2, forms a covalent linkage with the C4b. Secondly, C4b with covalently attached C3b serves to form a high-affinity binding site for C5. Purified allotypes C4A3, C4B1 and C4A6 were used to compare these two activities of C4. Covalently linked C4b-C3b complexes were formed on sheep erythrocytes with similar efficiency by using C4A3 and C4B1, indicating that the two isotypes behave similarly as acceptors for covalent attachment of C3b. C4A6 showed normal efficiency in this function. However, cells bearing C4b-C3b complexes made from C4A6 contained only a small number of high-affinity binding sites for C5. Therefore a lack of binding of C5 to the C4b C3b complexes is the reason for the inefficient formation of C5 convertase by C4A6. The small number of high-affinity binding sites created, when C4A6 was used, were tested for inhibition by anti-C3 and anti-C4. Anti-C4 did not inhibit C5 binding, whereas anti-C3 did. This suggests that the sites created when C4A6 is used to make C3 convertase may be C3b-C3b dimers, and hence the low haemolytic activity of C4A6 results from the creation of low numbers of alternative-pathway C5-convertase sites.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2803239      PMCID: PMC1138894          DOI: 10.1042/bj2610743

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

Review 1.  The beta-Cys-gamma-Glu thiolester bond in human C3, C4, and alpha 2-macroglobulin.

Authors:  B F Tack
Journal:  Springer Semin Immunopathol       Date:  1983

2.  Amino acid sequence around the proposed thiolester bond of human complement component C4 and comparison with the corresponding sequences from C3 and alpha 2-macroglobulin.

Authors:  R D Campbell; J Gagnon; R R Porter
Journal:  Biosci Rep       Date:  1981-05       Impact factor: 3.840

3.  Polymorphism of human complement component C4.

Authors:  K T Belt; C Y Yu; M C Carroll; R R Porter
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

4.  Statement on the nomenclature of human C4 allotypes.

Authors:  G Mauff; C A Alper; Z Awdeh; J R Batchelor; J Bertrams; G Bruun-Petersen; R L Dawkins; P Démant; J Edwards; H Grosse-Wilde; G Hauptmann; P Klouda; L Lamm; E Mollenhauer; C Nerl; B Olaisen; G O'Neill; C Rittner; M H Roos; V Skanes; P Teisberg; L Wells
Journal:  Immunobiology       Date:  1983-03       Impact factor: 3.144

Review 5.  The proteolytic activation systems of complement.

Authors:  K B Reid; R R Porter
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

6.  The molecular basis for the difference in immune hemolysis activity of the Chido and Rodgers isotypes of human complement component C4.

Authors:  D E Isenman; J R Young
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

7.  A molecular basis for the two locus model of human complement component C4.

Authors:  M H Roos; E Mollenhauer; P Démant; C Rittner
Journal:  Nature       Date:  1982-08-26       Impact factor: 49.962

8.  The purification and properties of some less common allotypes of the fourth component of human complement.

Authors:  A W Dodds; S K Law; R R Porter
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

9.  A comparison of the properties of two classes, C4A and C4B, of the human complement component C4.

Authors:  S K Law; A W Dodds; R R Porter
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

10.  The origin of the very variable haemolytic activities of the common human complement component C4 allotypes including C4-A6.

Authors:  A W Dodds; S K Law; R R Porter
Journal:  EMBO J       Date:  1985-09       Impact factor: 11.598

View more
  2 in total

1.  Mutants of complement component C3 cleaved by the C4-specific C1-s protease.

Authors:  P Mathias; C J Carrillo; N E Zepf; N R Cooper; R T Ogata
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

2.  Combined total deficiency of C7 and C4B with systemic lupus erythematosus (SLE).

Authors:  O G Segurado; A A Arnaiz-Villena; P Iglesias-Casarrubios; J Martinez-Laso; J L Vicario; G Fontan; M Lopez-Trascasa
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.